Other substances

VHH-Fcs 1B-3F-2A

A tri-specific antibody/nanobody.

Phase of research

Potential treatment - pre-clinical evidence

How it helps

Antiviral

Drug status

Experimental

1
 Supporting references
0
 Contradictory references
0
 AI-suggested references
0
 Clinical trials

General information

VHH-Fcs 1B-3F-2A is a tri-specific antibody constructed by fusion of human IgG1 Fc to three single domain llama nanobodies with affinity to the SARS-CoV-2 spike protein RBD (Dong et al., 2020).

 

Supporting references

Link Tested on Impact factor Notes Publication date
Development of humanized tri-specific nanobodies with potent neutralization for SARS-CoV-2
Spike protein ACE2 In vitro Antibody 		HEK293 ACE2/TMPRSS2 cells; Expi293 cells expressing S1 protein (cytotoxicity assay) 4.00

Potently binds to the SARS-CoV-2 spike protein RBD, blocks the spike-ACE2 interaction, and inhibits SARS-CoV-2 pseudotyped virus infection of human cells in vitro.

 Oct/20/2020
Export (.csv)